latest news releases from the newsroom
Nano-Proprietary Signs Development, Purchase and License Agreement for Hydrogen Sensor Products
AUSTIN, Texas, July 6, 2004 (PRIMEZONE) -- Austin, Texas-based Nano-Proprietary (OTCBB:NNPP), through its subsidiary, Applied Nanotech, Inc. (ANI), today announced that it has entered into an exclusive development, purchase, and license agreement related to its hydrogen sensor products with an international company that specializes in the design, measurement, analysis, and development of electrical measuring equipment. The agreement is exclusive for the measurement of hydrogen in power transformers, tap changers, and breakers.
Atlantic Synergy, Inc. Announces It has Completed the Acquisition of Acies, Inc.
FORT PIERCE, Fla., July 6, 2004 (PRIMEZONE) -- Atlantic Synergy, Inc. (OTCBB:ASGY) and Acies, Inc., are pleased to announce that the companies have reached a definitive agreement whereby Atlantic Synergy will purchase 100% of all Acies' issued and outstanding shares for 26,150,000 common stock, newly issued Atlantic Synergy treasury shares. Consequent to the closing of this transaction Acies will become a wholly owned subsidiary of Atlantic Synergy and Atlantic Synergy will have 30,763,750 common stock shares issued and outstanding.
Canada Medicine Mart
Canada Medicine Mart Launches California Retail Prescription Drug Challenge
EDMONTON, Alberta, July 6, 2004 (PRIMEZONE) -- Canada Medicine Mart, a leading online Canadian pharmacy, today announced the launch of its new 30-day Retail Prescription Drug Challenge. The challenge runs from July 15th, 2004, through August 15th, 2004. It offers California residents an alternative means to purchase the higher-priced prescription drugs they may now acquire through major U.S. retail chain outlets, such as Walgreens, Eckerd, CVS, and Rite Aid.
HepaLife Technologies, Inc.
HepaLife Receives Approval for Trading on Frankfurt Stock Exchange
VANCOUVER, British Columbia, July 6, 2004 (PRIMEZONE) -- HepaLife Technologies, Inc. (OTCBB:HPLF), an early stage biotechnology company focused on developing the first of its kind artificial liver device and proprietary in vitro toxicology and pre-clinical drug testing platforms, today announced that it has met admission requirements and has been accepted for listing onto the Frankfurt Stock Exchange. Trading commenced on July 5, 2004, under the symbol HL1 and the German cusip (WKN) number 500625. HepaLife Technologies will continue to trade on the OTCBB market.